Arrayit, DOCRO Sign Deal Aimed at FDA Approval | GenomeWeb

NEW YORK (GenomeWeb News) – Arrayit said today it has inked a professional services master agreement with Diagnostic Oncology Research Organization to aid it in obtaining approval from the US Food and Drug Administration for its tests.

The agreement will serve as a blueprint for submitting Arrayit's OvaDx presymptomatic ovarian cancer monitoring and screening test, a secondary Parkinson's disease diagnostic test, and other tests in the company's pipeline.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.